Universität Wien
Warning! The directory is not yet complete and will be amended until the beginning of the term.

040760 UK Health- and Pharmaceutical Economics (BA) (2024S)

4.00 ECTS (2.00 SWS), SPL 4 - Wirtschaftswissenschaften
Continuous assessment of course work
Moodle

Registration/Deregistration

Note: The time of your registration within the registration period has no effect on the allocation of places (no first come, first served).

Details

max. 30 participants
Language: German

Lecturers

Classes (iCal) - next class is marked with N

  • Friday 15.03. 13:15 - 18:15 Hörsaal 10 Oskar-Morgenstern-Platz 1 2.Stock
  • Saturday 16.03. 09:45 - 13:00 Hörsaal 10 Oskar-Morgenstern-Platz 1 2.Stock
  • Friday 03.05. 13:15 - 18:15 Hörsaal 10 Oskar-Morgenstern-Platz 1 2.Stock
  • Saturday 04.05. 09:45 - 13:00 Hörsaal 10 Oskar-Morgenstern-Platz 1 2.Stock
  • Friday 07.06. 13:15 - 18:15 Hörsaal 10 Oskar-Morgenstern-Platz 1 2.Stock
  • Saturday 08.06. 09:45 - 11:15 Hörsaal 10 Oskar-Morgenstern-Platz 1 2.Stock

Information

Aims, contents and method of the course

Part 1: Health Care Systems
• Forms of Delivery of Medical Care
• Paying Providers
• Physicians as Suppliers of Medical Services
• Austrian Health Care System
Literature:
Breyer, F./Zweifel, P. Kifmann, M (2013), Gesundheitsökonomik, Springer. (Chapters 8, 10, 12)

Part 2: Health Economic Evaluation
• Health Technology Assessment (HTA) across countries
• Cost Effectiveness analysis
• Cost utility analysis
• Cost benefit analysis
• Comparative effectiveness
• Decision analytic modeling (e.g. Markov Models)
• Evidenced based Medicine
Literature:
Drummond, M/Sculpher, M./Torrance, G./O’Brien, B./Stoddart, G. (2015), Methods for the Economic Evaluation of Health Care Programmes, Oxford University Press (Chapters 5, 6, 7, 9)
Additional reading:
Schöffski, O. Graf v.d. Schulenburg, M. (Hg.) (2008), Gesundheitsökonomische Evaluationen, Springer.

Part 3 Pharmaceutical Economics
• The pharmaceutical Industry
• Pharmaceutical R&D process
• Costs and returns on pharmaceutical R&D
• Pricing Pharmaceuticals
• Pharmaceutical Regulation (e.g. patent legislation)
• Drug Marketing

Literature:
Schweitzer, S. (2007), Pharmaceutical Economics and Policy, Oxford University Press. (Chapters 1, 4, 6, 8, 12)

Assessment and permitted materials

Assigned Presentation (15 -20 Min)
Written final Exam

Minimum requirements and assessment criteria

Presentation and exam both contribute 50% to final grade.
To achieve a positive grade in the test, at least 50% of the points in the written test are necessary

Examination topics

.

Reading list

Foliensatz wird auf moodle bereitgestellt

Zusätzlich:
Breyer, F./Zweifel, P. Kifmann, M (2013), Gesundheitsökonomik, Springer. (Chapters 8, 10, 12)
Drummond, M/Sculpher, M./Torrance, G./O’Brien, B./Stoddart, G. (2015), Methods for the Economic Evaluation of Health Care Programmes, Oxford University Press (Chapters 5, 6, 7, 9)
Schöffski, O. Graf v.d. Schulenburg, M. (Hg.) (2008), Gesundheitsökonomische Evaluationen, Springer.
Schweitzer, S. (2007), Pharmaceutical Economics and Policy, Oxford University Press. (Chapters 1, 4, 6, 8, 12)

Association in the course directory

Last modified: We 31.07.2024 11:25